Executive Summary
Our team at Dabrico developed this report based on an extensive analysis of 343 pages of publicly available 2025 Form 483 observations and FDA Warning Letters citing visual inspection deficiencies in pharmaceutical manufacturing. While the specific findings vary by facility and product type, the regulatory expectation is clear and consistent: visual inspection must function as a validated, risk-based quality control system. It cannot be used as an informal “catch step” to compensate for weak upstream controls, inadequate contamination prevention, or poor process capability.
Across the reviewed letters, the FDA repeatedly emphasizes that inspection performance is inseparable from broader quality system effectiveness. Deficiencies in inspection programs often reflect deeper issues in governance, process control, and scientific justification. In particular, FDA expectations extend beyond operator performance to include program design, validation of inspection conditions, defect classification rigor, and the ability to detect, trend, and respond to defects in a systematic and reproducible way.
Key Themes Identified
Across the analyzed letters, several recurring deficiencies emerged:
- Inspector qualification and training gaps
- Lack of documented training records
- No structured requalification programs
- Inadequate challenge sets that fail to simulate real-world defects
- Weak defect trending and lack of defect-specific limits
- Overreliance on broad defect categories (e.g., “critical,” “major”)
- No defect-type-level monitoring or escalation triggers
- Absence of alert/action limits tied to specific defect profiles
- Insufficient scientific justification for inspection conditions
- Unvalidated light intensity levels
- No rationale for inspection duration or speed
- Inconsistent use of background contrast
- Sampling and AQL weaknesses
- No statistical justification for sampling plans
- Reinspection allowed without investigation
- Decision rules that enable repeated attempts to pass failing lots
- Inadequate investigations
- Root causes not identified or poorly supported
- Failure to characterize particulates or defect types
- Risk assessments that minimize patient impact
- Overreliance on visual inspection in cleaning verification
- “Visually clean” used as sole acceptance criterion
- No analytical or microbiological confirmation
- Increased cross-contamination risk
These deficiencies are most frequently observed in higher-risk manufacturing environments, particularly sterile operations where the consequences of failure are directly tied to patient safety. Visible particulates and container closure defects are recurring concerns, especially in injectable and ophthalmic drug products. In these settings, FDA consistently links inspection performance to contamination control, defect detection capability, and the rigor of investigations and corrective actions.
Importantly, visual inspection deficiencies are not limited to final product release. The findings extend into adjacent systems such as equipment cleaning verification, cross-contamination controls, and broader process validation gaps. This reinforces the agency’s view that inspection is part of an interconnected quality system rather than a standalone checkpoint.
Strategic Takeaway
The central takeaway for pharmaceutical manufacturers is that visual inspection must be designed and managed as an integrated “inspection plus prevention” system. This includes implementing a risk-based defect taxonomy aligned to specific products and containers, validating inspection parameters such as lighting, timing, and environmental conditions, and establishing statistically sound sampling and escalation logic.
Equally important is the ability to trend defects at a granular level with defined alert and action limits, and to conduct investigations that trace issues back to upstream sources such as raw materials, equipment condition, aseptic practices, and cleaning effectiveness. Organizations that adopt this systems-level approach will be better positioned to meet regulatory expectations while improving process capability and product quality.
About the Analysis
This analysis includes FDA Warning Letters where the product category is drugs (human pharmaceuticals) and where the letter text explicitly references visual inspection as a deficient or critical control. Included manufacturing contexts span finished dosage manufacturing, sterile compounding under Section 503B, and active pharmaceutical ingredient (API) production.
Data Limitations
Two practical limitations affect completeness. First, the scope is limited to deficiencies explicitly labeled as “visual inspection,” meaning closely related issues may be excluded if not described using that terminology. Second, FDA publishes Warning Letters individually rather than as structured datasets, requiring manual review and synthesis of each document. Despite these constraints, the consistency of themes across letters provides a clear and reliable view of regulatory expectations.
Key Findings on Visual Inspection Deficiencies
The chart below summarizes how frequently key visual inspection deficiencies appeared across the analyzed 2025 FDA Warning Letters. While individual letters often cite multiple issues, clear patterns emerge in where inspection programs are breaking down.
1. Visual Inspection as a System Capability
FDA positions visual inspection as a fully integrated quality system capability rather than a standalone manual task. This means firms are expected to implement structured program design and governance, including clearly defined defect libraries, standardized classification systems, and robust qualification and requalification processes. Inspection parameters such as lighting, timing, and environment must be scientifically justified and consistently applied, while ongoing monitoring frameworks should include defect trending, performance tracking, and formal escalation pathways to ensure sustained system reliability.
What the Major Deficiency Themes Mean
The most common deficiencies highlight failures in demonstrating that inspection systems can reliably detect real-world defects under actual operating conditions. FDA findings frequently point to incomplete or missing training documentation, lack of periodic requalification, outdated or ineffective defect challenge kits, and poorly defined inspection timing standards. These gaps indicate not just training issues, but systemic weaknesses in proving inspection effectiveness and consistency over time.
2. Defect Trending and Defect-Specific Limits
A major governance concern is the lack of defect-level visibility and control. Many firms rely on broad defect categories rather than tracking specific defect types such as fibers, glass, or bubbles. FDA expects detailed trending of individual defect types over time, supported by defined alert and action limits. Additionally, reinspection practices must be governed by clear procedures and escalation thresholds, rather than ad hoc decisions, to ensure meaningful control of product quality risks.
3. Sampling and AQL Weaknesses
FDA criticism extends beyond missing statistical justification and focuses on flawed decision-making frameworks. In several cases, firms allowed repeated 100% inspections after failures or continued product release without proper investigation. These approaches resemble “testing into compliance,” where inspection is used to justify release rather than assess true process capability, undermining the role of inspection as a quality control mechanism.
4. Investigation Quality
Regulators emphasize that investigations must reflect realistic patient risk, particularly for sterile products. Findings include cases where firms minimized the severity of visible particulates in high-risk applications and maintained unacceptable defect limits even after revisions. Common shortcomings include lack of root cause analysis, absence of particulate characterization, and failure to distinguish between defects identified during inspection and those found post-release, limiting the effectiveness of corrective actions.
5. Inspection Conditions
Inspection parameters are treated as critical scientific variables that must be validated and controlled. FDA expects firms to justify factors such as light intensity, background contrast, inspection duration, and environmental conditions, and to ensure these are consistently applied across operations. Deficiencies often arise from inconsistent requirements across documentation and lack of verification that conditions are maintained, which can directly impact defect detection capability.
Patterns by Manufacturing Context
FDA findings show that visual inspection deficiencies are not isolated issues but are closely tied to specific manufacturing environments and product risks. The agency consistently evaluates how well inspection programs are integrated with upstream processes, contamination controls, and overall quality system performance. Weaknesses often emerge where inspection is treated as a downstream safety net rather than part of a broader, risk-based control strategy.
Sterile Drugs and Visible Particulate Risk
A large share of observations centers on sterile products, where visible particulates and container defects pose direct patient safety risks. FDA repeatedly connects inspection performance to the ability to prevent contamination, detect defects effectively, conduct rigorous investigations, and implement meaningful CAPA. In these contexts, inspection is expected to function as both a detection mechanism and a feedback loop into process improvement, not simply a final check.
Regulatory Expectations Referenced
FDA frequently anchors its expectations in compendial guidance such as USP <1790> and USP <771>, reinforcing a lifecycle approach to inspection. This includes requirements for 100% unit inspection where appropriate, as well as enhanced inspection conditions like optimized lighting and background contrast. Where traditional inspection is limited, such as with opaque containers, firms are expected to implement alternative, scientifically justified approaches to ensure product quality.
Outsourcing Facilities (503B)
For outsourcing facilities, a recurring issue is the gap between having documented procedures and operating a complete, functional inspection program. While SOPs may exist, they often lack essential elements such as defined 100% inspection requirements, AQL procedures, operator qualification criteria, defect classification systems, and controlled inspection environments. Execution gaps further compound the issue, with missing batch record evidence, insufficient training documentation, inconsistent requirements across documents, and incomplete or outdated defect kits, all pointing to systemic weaknesses in program implementation.
Strategic Recommendations
Lock Down Inspection Conditions with Scientific Justification
Inspection conditions should be treated as a validated process state, not an operator preference. Firms are expected to define, control, and justify critical parameters such as lighting intensity, background contrast, inspection timing, speed, and ergonomic setup. These variables directly impact detection capability and must be consistently applied and supported by documented evidence demonstrating that conditions are appropriate and reproducible in practice.
Eliminate “Testing into Compliance”
FDA findings emphasize the need for clear, risk-based decision frameworks governing inspection outcomes. Organizations should establish defined rules for when reinspection is permissible, when investigations must be initiated, and when production should be halted or lots quarantined. Failures should trigger meaningful investigation and root cause analysis, rather than repeated inspection cycles that attempt to justify product release without addressing underlying issues.
Use Inspection as a Control, Not a Compensating Mechanism
Inspection should function as a control within a capable process, not as a downstream fix for systemic deficiencies. High reject rates are a signal of poor process capability and should prompt deeper analysis and upstream remediation. Relying on inspection to remove defects after they occur reflects a weak quality system and is a recurring concern in FDA observations.
Treat Training, Qualification, and Defect Libraries as Validated Assets
Training programs, qualification processes, and defect libraries must be managed as validated components of the inspection system. This includes maintaining qualified defect sets and realistic challenge kits, implementing periodic requalification, and ensuring consistent, documented adherence to inspection procedures. Most importantly, programs must demonstrate that inspectors can reliably detect relevant defect types under real conditions, not just complete training requirements.
Strengthen Cleaning Verification Programs
FDA guidance makes clear that visual inspection alone is not sufficient for cleaning verification, particularly for high-risk equipment. Effective programs should incorporate defined residue limits, validated analytical methods, and risk-based cleaning strategies. This ensures that cleanliness is measured and controlled scientifically, rather than relying on subjective visual assessments that may fail to detect critical contamination risks.
Final Perspective
FDA’s 2025 Warning Letters reinforce a clear and consistent expectation: visual inspection is not a fallback or “catch step,” but a scientifically grounded, system-level control. It must be fully integrated with process capability, contamination prevention strategies, and broader quality system governance. Organizations that treat inspection as part of an interconnected control system, rather than an isolated activity, are better positioned to strengthen compliance, reduce risk, and ultimately protect patient safety.
